0 months ago

Emkay retains Buy on Park Medi World, sees 32% upside

Emkay retains Buy on Park Medi World, sees 32% upside
Stock to buy after Q1 results 2026: Emkay sees over 32% upside in this healthcare stock · livemint.com

There is a hospital company called Park Medi World.

A financial expert firm called Emkay studies stocks and tells people which ones are good to buy.

Emkay looked at Park Medi World's latest results, which were for the June quarter.

The company made more money than before, and even more than experts expected.

Its revenue went up 19% compared to the same time last year.

Its profit grew even faster, going up 31%.

Because the company is doing so well, Emkay thinks its share price will rise by about 32%.

So Emkay told investors to keep buying the stock and set a higher target price.

The company also plans to add many more hospital beds over the next two years.

Emkay warned that delays in payments from government schemes and new markets are risks to watch.

Key facts

Rating
Buy (retained)
Target price
₹375 per share (raised from ₹350)
Latest closing price
₹285 per share
Implied upside
~32%
Q1FY27 revenue
₹4.8 billion, up 19% YoY
Q1FY27 EBITDA
₹1.2 billion, up 20% YoY
Q1FY27 PAT
₹825 million, up 31% YoY
FY27 guidance
24% revenue growth and 19% EBITDA growth

Sources

Related news